Stockscreener 앱 받기
26.22
2.14%
0.55
시간 외 거래:
26.65
0.43
+1.64%
Arcutis Biotherapeutics Inc 주식(ARQT)의 최신 뉴스
[144] Arcutis Biotherapeutics, Inc. SEC Filing - Stock Titan
Arcutis Biotherapeutics (ARQT) Slips Slightly as Stock Holds Above Key SupportZero Gamma Level - newsline.com
Arcutis (ARQT) director amends filing to correct indirect share count - Stock Titan
Arcutis Biotherapeutics touts ZORYVE growth, FDA catalysts and cash-flow positive status - MSN
Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy? - Yahoo Finance
Arcutis Biotherapeutics, Inc. (ARQT) reports Q1 loss, beats revenue estimates - MSN
GW&K Investment Management LLC Sells 163,461 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Acquired Rep. Gilbert Ray Cisneros, Jr. - MarketBeat
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status - sharewise.com
Arcutis (ARQT) director receives RSU grant and 16,667-share stock option - Stock Titan
[Form 4] Arcutis Biotherapeutics, Inc. Insider Trading Activity - Stock Titan
Arcutis Stockholders Approve Proposals at 2026 Meeting - TipRanks
Arcutis Biotherapeutics (ARQT) 2026 meeting OKs directors, auditor and executive pay - Stock Titan
Antag Therapeutics Elects Keith Leonard as Chairman of its Board of Directors - GlobeNewswire Inc.
Geode Capital Management LLC Has $79.97 Million Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Six new Arcutis hires receive 44,000 restricted stock units - Stock Titan
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 sees revenue beat, EPS miss - Investing.com
Arcutis Biotherapeutics EVP Masaru Matsuda sells $192k in stock - Investing.com
ARCUTIS BIOTHERAPEUTICS INC (ARQT) Stock Chart - ChartMill
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology - StreetInsider
New Expert Consensus Provides Age-Specific Guidance for - GlobeNewswire
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Hillsdale Investment Management Inc. Invests $5.21 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
ARQT Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ARQT News | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
(ARQT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
A Quick Look at Today's Ratings for Arcutis Biotherapeutics(ARQT.US), With a Forecast Between $34 to $37 - Moomoo
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference - The Globe and Mail
Insiders At Arcutis Biotherapeutics Sold US$4.4m In Stock, Alluding To Potential Weakness - Moomoo
Arcutis Biotherapeutics (ARQT) Price Target Increased by 32.62% to 31.62 - MSN
How (ARQT) Movements Inform Risk Allocation Models - Stock Traders Daily
Number of shareholders of Arcutis Biotherapeutics, Inc. – NASDAQ:ARQT - TradingView
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound (NASDAQ:ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - FinancialContent
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. By Investing.com - Investing.com UK
Arcutis Biotherapeutics SVP CFO Latha Vairavan sells $9,156 in stock. - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock - Investing.com UK
Arcutis EVP, CMO Burnett sells $4,673 in common stock By Investing.com - Investing.com South Africa
Arcutis (ARQT) CFO tax-related sale of 435 shares after RSU vesting - Stock Titan
Arcutis Biotherapeutics (ARQT) officer sells 222 shares to cover RSU tax - Stock Titan
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push By Investing.com - Investing.com Nigeria
Arcutis Q1 2026 slides: revenue surges 65% amid expansion push - Investing.com
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Arcutis Biotherapeutics Q1 2026 misses EPS expectations - Investing.com Nigeria
State Street (NYSE: STT) holds 6.30M shares of Arcutis (5.1%) - Stock Titan
2.60%
0.94%
자본화:
|
볼륨(24시간):